Drug repurposing is a promising strategy that involves identifying new therapeutic uses for existing or experimental drugs. It offers significant advantages over developing new drugs, such as reduced risk, faster development timelines, and lower costs. In the context of cardiovascular diseases (CVDs), which have the highest mortality rate across the globe, drug repurposing presents an opportunity to address the growing need for effective therapies. Despite the importance of CVDs, there has been a noticeable decline in the development of novel cardiovascular drugs. Drug repurposing is the strategy of taking an existing, approved, or investigational drug and using it for a new. Drug repurposing can bridge this gap by identifying existing drugs that could be effective for cardiovascular conditions. The process involves computational approaches, such as molecular docking and signature matching, along with experimental techniques like phenotypic screening and clinical data analysis, for the purpose of discovering new uses for drugs. However, despite its potential benefits, drug repurposing faces regulatory challenges. Regulatory authorities, such as the FDA and EMA, may require more conclusive data to ensure the safety and efficacy of repurposed drugs for new indications. The lack of clarity regarding the regulatory pathway for repurposed drugs can result in delays and increased costs. Additionally, the repurposing of drugs for cardiovascular conditions requires rigorous data from preclinical and clinical studies to demonstrate their effectiveness and manage any unforeseen side effects. Despite these hurdles, drug repurposing remains a promising and efficient strategy for developing new cardiovascular therapies to address the growing burden of cardiovascular diseases worldwide.